Well Referenced

Tag: OGFr

Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy

This 2024 review explores the potential of low-dose naltrexone (LDN) as an adjunct in cancer treatment. LDN functions by transiently blocking the opioid growth factor receptor (OGFr), leading to a compensatory increase in opioid growth factor (OGF) levels, which inhibits cancer cell proliferation. Additionally, LDN modulates the immune system by

Read More »
June 26, 2025 No Comments

Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

This 2021 study investigates the antitumor effects of low-dose naltrexone (LDN) on cervical cancer. LDN treatment upregulated the expression of the opioid growth factor receptor (OGFr) and suppressed the PI3K/AKT/mTOR signaling pathway, leading to reduced proliferation, migration, and invasion of cervical cancer cells in vitro. In vivo, LDN inhibited tumor

Read More »
June 26, 2025 No Comments